Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

Lancet Oncology

Volumn 6, Issue 9, 2005, Pages 724-727

  Grimpen, Florian ^a   Yip, Desmond ^a   McArthur, Grant ^b   Waring, Paul ^b   Goldstein, David ^c   Loughrey, Maurice ^b   Beshay, Victoria ^b   Chong, Guan ^a  

^a CANBERRA HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ANEMIA; ARTICLE; CARCINOGENESIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MALE; MUTATIONAL ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC ERRORS; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GLUCOSE-6-PHOSPHATE; HUMANS; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SEQUENCE DELETION;

EID: 24044434901     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70321-1     Document Type: Article

References (15)

1. JA Crosby CN Catton A Davis et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database Ann Surg Onc 8 2001 50-59
2. MC Heinrich CL Corless GD Demetri et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342-4349
3. J Verweij P Casali J Zalcberg et al. A higher dose of imatinib improves progression free survival in gastro-intestinal stromal tumors Lancet 364 2004 1127-1134
4. BP Rubin S Singer C Tsao et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 2001 8118-8121
5. ML Lux BP Rubin TL Biase et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 156 2000 791-795
6. MC Heinrich CL Corless A Duensing et al. PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708-710
7. K Kinoshita K Isozaki S Hirota et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors J Gastroenterol Hepatol 18 2003 147-151
8. Y Zermati P De Sepulveda F Feger et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms Oncogene 22 2003 660-664
9. K Kemmer CL Corless JA Fletcher et al. KIT mutations are common in testicular seminomas Am J Pathol 164 2004 305-313
10. M Debiec-Rychter J Cools H Dumez et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology 128 2005 270-279
11. ME Gorre M Mohammed K Ellwood et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876-880
12. T Wakai T Kanda S Hirota et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation Br J Cancer 90 2004 2059-2061
13. LL Chen JC Trent EF Wu et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumours Cancer Res 64 2004 5913-5919
14. S Stroobants J Goeminne M Seegers et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2003 2012-2020
15. P Jager J Gietema W van der Graaf et al. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: Best monitored with FDG PET Nucl Med Commun 25 2004 433-438